Parker Waichman, a national law firm, has now filed five (5) separate lawsuits where each Plaintiff alleged that he or she developed NAION after taking ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Explore Allurion Technologies' Q2 2025 strategic shift focusing on combination therapies for obesity management, R&D innovation, and long-term ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Ozempic users who suffer strokes appear to have much lower death rates and better long-term survival. Evidence points to a ...

Although new medicines can help you lose weight faster and healthier than ever, a new psychology is needed to keep your ...

Texas Attorney General Ken Paxton said the state is suing Eli Lilly for allegedly bribing clinicians to prescribe its GLP-1 ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

This episode of Pharma Pulse dives into Cardinal Health’s acquisition of Solaris Health to strengthen specialty services, how ...